Results differ among individuals, and multiple sessions may be required for optimal outcomes
[49] In a phase III double-blind, randomized, controlled trial supported by Eli Lilly, nondiabetic adults with a body mass index of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, were randomized to receive once-weekly, subcutaneous tirzepatide (5, 10, or 15 mg) or placebo
But trust me, there is so much more to this topic
doi: 10.1530/EC-21-0449 CrossRef Google Scholar View reference in article 9 ZhaoYGaoPSunFLiQChenJYuHet al
Although it is not a primary treatment option, glutathione may also reduce the risk of cancer by protecting the body from oxidative stress